UNSPSC 51343504: Adefovir dipivoxil

This classification denotes an acyclic nucleotide adenine antiviral with the molecular formula C20H32N5O8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6Q8Z01514, chemically known as propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) ester but more generally known as adefovir dipivoxil, which bears US NIH Compound Identifier 60871.

UNSPSC 51343504 Adefovir dipivoxil is a Commodity code, but the recent state and local opportunities tagged under it show little relevant activity tied to the code's nominal scope. The source contains four recent solicitations — three genuinely unrelated to adefovir dipivoxil (a pharmaceutical active ingredient for hepatitis B treatment) and one RFI from the Texas Health and Human Services Commission on direct-to-manufacturer prescription programs that addresses pharmacy strategy broadly rather than any specific drug product. The Seminole County naloxone procurement, the City of Tampa medical and first aid supplies bid, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic pharmaceuticals RFP are all legitimate state and local health-sector purchases, but none targets adefovir dipivoxil specifically or treats it as a line item. The code appears to carry a misclassification or tagging error across recent postings, suggesting minimal or no direct procurement activity for adefovir dipivoxil itself at the state and local level during this period.

State and local procurement under this code, if present, likely occurs through larger pharmaceutical cooperative purchasing frameworks or health department inventory procurements, but no recent opportunities in the source demonstrate active demand for adefovir dipivoxil as a distinct commodity. The geographic spread implied by the unrelated opportunities spans Florida, Texas, and Minnesota, reflecting broader health-sector purchasing activity, but none of these jurisdictions have issued a specific solicitation for adefovir dipivoxil. Firms pursuing this code should verify that their target customers intend to procure the drug directly rather than assume the UNSPSC classification reflects genuine buying intent; the current record suggests this code warrants close monitoring for classification corrections before resource allocation.